Flow cytometric signature of CD371-positive B-cell acute lymphoblastic leukemia
Objectives Multiparametric flow cytometry (MFC) aids in the diagnosis and management of B-cell acute lymphoblastic leukemia (B-ALL) by establishing a baseline immunophenotype for leukemic cells and measuring minimal residual disease (MRD) throughout the course of treatment. Aberrant expression patte...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-10-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605231203842 |
| _version_ | 1827795560816443392 |
|---|---|
| author | Hind Shakah Abdelghani Tbakhi Saleh Khudirat Ruba Al Abweh Nabil Hasasna Alaa Alwhaidi Abdallah Khoujah Fareed Barakat |
| author_facet | Hind Shakah Abdelghani Tbakhi Saleh Khudirat Ruba Al Abweh Nabil Hasasna Alaa Alwhaidi Abdallah Khoujah Fareed Barakat |
| author_sort | Hind Shakah |
| collection | DOAJ |
| description | Objectives Multiparametric flow cytometry (MFC) aids in the diagnosis and management of B-cell acute lymphoblastic leukemia (B-ALL) by establishing a baseline immunophenotype for leukemic cells and measuring minimal residual disease (MRD) throughout the course of treatment. Aberrant expression patterns of myeloid markers in B-ALL are also examined during long-term surveillance. Here, we investigated the utility of the newly described myeloid marker cluster of differentiation (CD)371 in MRD surveillance via MFC in patients with CD371-positive B-ALL. Methods Eight-color MFC with standard panels (including CD371) was used to evaluate 238 patients with newly diagnosed B-ALL. Expression levels of key markers were retrospectively assessed at diagnosis, as well as days 15 and 33 of therapy. Results CD371 was expressed in 8.4% of patients with B-ALL. CD371 positivity was associated with older age at diagnosis, higher expression levels of CD34 and CD38, and lower expression levels of CD10 and CD20. Residual leukemic cells demonstrated decreased CD10 expression and increased CD45 expression after therapy, whereas CD371 expression remained stable. Conclusions Patients with CD371-positive B-ALL exhibit a specific signature that merits further analysis, particularly because it has been associated with DUX4 rearrangement. |
| first_indexed | 2024-03-11T18:52:15Z |
| format | Article |
| id | doaj.art-fe15e9ab2a05449ba277b9dc3f115eb7 |
| institution | Directory Open Access Journal |
| issn | 1473-2300 |
| language | English |
| last_indexed | 2024-03-11T18:52:15Z |
| publishDate | 2023-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of International Medical Research |
| spelling | doaj.art-fe15e9ab2a05449ba277b9dc3f115eb72023-10-11T10:33:37ZengSAGE PublishingJournal of International Medical Research1473-23002023-10-015110.1177/03000605231203842Flow cytometric signature of CD371-positive B-cell acute lymphoblastic leukemiaHind ShakahAbdelghani TbakhiSaleh KhudiratRuba Al AbwehNabil HasasnaAlaa AlwhaidiAbdallah KhoujahFareed BarakatObjectives Multiparametric flow cytometry (MFC) aids in the diagnosis and management of B-cell acute lymphoblastic leukemia (B-ALL) by establishing a baseline immunophenotype for leukemic cells and measuring minimal residual disease (MRD) throughout the course of treatment. Aberrant expression patterns of myeloid markers in B-ALL are also examined during long-term surveillance. Here, we investigated the utility of the newly described myeloid marker cluster of differentiation (CD)371 in MRD surveillance via MFC in patients with CD371-positive B-ALL. Methods Eight-color MFC with standard panels (including CD371) was used to evaluate 238 patients with newly diagnosed B-ALL. Expression levels of key markers were retrospectively assessed at diagnosis, as well as days 15 and 33 of therapy. Results CD371 was expressed in 8.4% of patients with B-ALL. CD371 positivity was associated with older age at diagnosis, higher expression levels of CD34 and CD38, and lower expression levels of CD10 and CD20. Residual leukemic cells demonstrated decreased CD10 expression and increased CD45 expression after therapy, whereas CD371 expression remained stable. Conclusions Patients with CD371-positive B-ALL exhibit a specific signature that merits further analysis, particularly because it has been associated with DUX4 rearrangement.https://doi.org/10.1177/03000605231203842 |
| spellingShingle | Hind Shakah Abdelghani Tbakhi Saleh Khudirat Ruba Al Abweh Nabil Hasasna Alaa Alwhaidi Abdallah Khoujah Fareed Barakat Flow cytometric signature of CD371-positive B-cell acute lymphoblastic leukemia Journal of International Medical Research |
| title | Flow cytometric signature of CD371-positive B-cell acute lymphoblastic leukemia |
| title_full | Flow cytometric signature of CD371-positive B-cell acute lymphoblastic leukemia |
| title_fullStr | Flow cytometric signature of CD371-positive B-cell acute lymphoblastic leukemia |
| title_full_unstemmed | Flow cytometric signature of CD371-positive B-cell acute lymphoblastic leukemia |
| title_short | Flow cytometric signature of CD371-positive B-cell acute lymphoblastic leukemia |
| title_sort | flow cytometric signature of cd371 positive b cell acute lymphoblastic leukemia |
| url | https://doi.org/10.1177/03000605231203842 |
| work_keys_str_mv | AT hindshakah flowcytometricsignatureofcd371positivebcellacutelymphoblasticleukemia AT abdelghanitbakhi flowcytometricsignatureofcd371positivebcellacutelymphoblasticleukemia AT salehkhudirat flowcytometricsignatureofcd371positivebcellacutelymphoblasticleukemia AT rubaalabweh flowcytometricsignatureofcd371positivebcellacutelymphoblasticleukemia AT nabilhasasna flowcytometricsignatureofcd371positivebcellacutelymphoblasticleukemia AT alaaalwhaidi flowcytometricsignatureofcd371positivebcellacutelymphoblasticleukemia AT abdallahkhoujah flowcytometricsignatureofcd371positivebcellacutelymphoblasticleukemia AT fareedbarakat flowcytometricsignatureofcd371positivebcellacutelymphoblasticleukemia |